|
|
Post by Hot Christian Stocks on Mar 6, 2014 8:18:26 GMT -5
$NVLX Recent Events Effectively De-Risk Nuvilex, Inc. BALTIMORE, Maryland, March 6, 2014 /PRNewswire/ --Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, recently published a new research update on Nuvilex Inc. (OTCQB: NVLX). In the update, senior analyst Rob Goldman outlines his latest thesis. "In our view, with institutional funding in place to a potential $27 million, Nuvilex has been transformed from an also-ran to a soon-to-be-prime time player in the biotech and medical marijuana arenas. Moreover, this funding agreement validates the Company's technology and effectively de-risks the stock." Nuvilex is a biotechnology company with the rights to a novel cellulose-based live-cell encapsulation technology, called Cell-in-a-Box™, that will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. Nuvilex's treatment for pancreatic cancer involves the use of the widely used anticancer prodrug, ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. Nuvilex's subsidiary, Medical Marijuana Sciences, Inc., is dedicated to the development of cancer treatments based upon the well-known chemical constituents of marijuana. Nuvilex is exploring ways in which the Cell-in-a-Box™ technology may play a role in these efforts. According to Goldman, now that an institution has validated the company, attention will be focused on fundamentals and a series of future milestones and executable events, which means a higher future valuation for the company and all three of its treatment categories: cancer, diabetes, and medicinal marijuana. Moreover, since all three categories address high profile, multi-billion dollar markets, the associated future valuation adjustments could be substantial as milestone events are executed. www.stockwatch.com/News/Item.aspx?bid=U-prenUK201403052285A-U%3aNVLX-20140306&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 6, 2014 13:33:22 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 7, 2014 9:05:54 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 10, 2014 8:10:15 GMT -5
$NVLX - Nuvilex appointed Dr. Rabe, a leading figure in the medical marijuana field quoted in article about a minister's daughter stating - Cannabis 'a gift from God' "Patients often come into my office and drop down a brown bag full of pill bottles on my desk and say, 'I'm off Oxycodone; I'm off muscle relaxants. I'm off Ambien; I'm off Trazodone,' because medical cannabis does the job better," said Rabe, who runs Centric Wellness in San Diego www.cnn.com/2014/03/07/health/cannabis-pain/ |
|
|
|
Post by Hot Christian Stocks on Mar 11, 2014 8:05:47 GMT -5
$NVLX Nuvilex Appoints CEO and President of Austrianova to Scientific Advisory BoardNuvilex Appoints CEO and President of Austrianova to Scientific Advisory Board Dr. Brian Salmons Indispensable for Development of Cannabis-Based Cancer Treatments SILVER SPRING, Md., March 11, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of deadly diseases, announced today that its subsidiary, Medical Marijuana Sciences, Inc., has appointed Brian Salmons, Ph.D., CEO and President of Nuvilex's partner Austrianova, to its Scientific Advisory Board. Dr. Salmons, together with Professor Dr. Walter H. Günzburg, invented and developed the live-cell encapsulation technology now known as Cell-in-a-Box(TM) which has been licensed by Nuvilex for the development of treatments for cancer and diabetes. It is expected that, given his expertise in this and other aspects of the development of disease treatments, Dr. Salmons will play a pivotal role as Medical Marijuana Sciences goes forward with its cannabis-based cancer treatments. Dr. Brian Salmons received his Ph.D. in London. After research positions in the U.S.A., Switzerland and at the Ludwig Maximilian University in Munich, Germany, Dr. Salmons became the Scientific Director of the European biotech/vaccine company, Bavarian Nordic, and was intricately involved in taking the company to an IPO. Bavarian Nordic was sponsor of the Phase1/2 clinical trial in patients with advanced, inoperable pancreatic cancer that involved the use of the combination of live-cell encapsulation and the anti-cancer prodrug ifosfamide. The results of this trial showed that the combination was safe and efficacious. These results were reported in reputable scientific literature and can be viewed by clicking here (please scroll down and click on blue title opposite "121-131"). In 2002, Dr. Salmons co-founded the biotech company, Austrianova, originally a "spin-off" from the Veterinary Medicine University in Vienna. He was instrumental in obtaining orphan drug status from the European Medicines Agency for its lead cell encapsulation product. In 2007, Dr. Salmons co-founded and became the CEO and President of Austrianova Singapore Pte. Ltd., an independent company established in Singapore to further develop the live-cell encapsulation technology as products for a variety of indications such as various forms of cancer, diabetes, neurodegenerative, cardiovascular and infectious diseases. Dr. Salmons is the author or co-author of over 120 peer-reviewed scientific articles and inventor of 8 patent families. Dr. Mark L. Rabe, Chairman of Medical Marijuana Sciences' Scientific Advisory Board, commented, "Dr. Salmons' acceptance of his appointment as a member of the Medical Marijuana Sciences Scientific Advisory Board is a major coup for Nuvilex. His complete knowledge of the Cell-in-a-Box(TM) encapsulation technology, and its many possible applications, will be invaluable as we strive to develop treatments for the deadliest of all cancers employing Cell-in-a-Box(TM) technology in combination with cannabis-based compounds." www.stockwatch.com/News/Item.aspx?bid=U-z10072083-U%3aNVLX-20140311&symbol=NVLX®ion=U
|
|
|
|
Post by Hot Christian Stocks on Mar 12, 2014 8:16:24 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 13, 2014 7:29:31 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 14, 2014 8:32:55 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 17, 2014 5:52:58 GMT -5
$NVLX New 10Q March 17, 2014 updated SS Common Stock, authorized 1,490,000,000 shares, $0.0001 par value, 602,958,014 and 482,106,348 shares issued and outstanding, respectively www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9858980 |
|
|
|
Post by Hot Christian Stocks on Mar 17, 2014 9:38:52 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 18, 2014 6:32:19 GMT -5
$NVLX presentation entitled "Cell-in-a-Box® Living Cell Encapsulation Products for Medical and Healthcare Use" given during the Clinical Trials section of the Convention's program, Dr. Günzburg reviewed the data from the early/mid-phase clinical trials that were done with the combination of Cell-in-a-Box® and the anti-cancer prodrug ifosfamide in patients with advanced inoperable pancreatic cancer; In those Phase 1 and Phase 2 clinical trials, the Cell-in-a-Box®/ifosfamide combination treatment was shown to essentially double the median survival time and percentage of one-year survivors over those seen in historical data for Gemzar® (gemcitabine), the only drug approved to date by the FDA as a single agent for the treatment of the disease. But unlike Gemzar®, Nuvilex's treatment had no serious treatment-related side effects associated with it because the dose of ifosfamide used in these trials was only one-third of that normally employed for cancer treatment. www.stockwatch.com/News/Item.aspx?bid=U-z10072790-U%3aNVLX-20140317&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 19, 2014 8:31:15 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Mar 20, 2014 8:05:26 GMT -5
$NVLX Contracts With Austrianova for cGMP-Compliant Cell-in-a-Box(R) Encapsulation of Cells for Clinical Trials NEW YORK, NY -- (Marketwired) -- 03/20/14 LiveDeal, Inc. (NASDAQ: LIVE) has generated a lot of attention since entering the online deal space and that attention has been well deserved. The company's instant, real-time concept makes more sense for users than the model used by long-time industry leaders like Groupon and others. Quite simply when business owners need more customers, they will create a promotion with an online deal site to help introduce their brand to potential consumers. LiveDeal launched its online deal platform in the restaurant industry, and with it, it's giving those restaurants the opportunity to reach customers immediately and in real-time. The introduction of this instant, real-time model gives www.livedeal.com plenty of potential as an on-going technology platform into the future. LiveDeal recently announced that it is ramping up its deal procurement team so that it can quickly grab market share. It is clear that the first step the company is taking is to build an audience. In technology, the name of the game is potential. Instagram, for instance, had 30 million users when it was acquired, but to arrive at a fair value for acquisition, the technology's future potential had to be included in the evaluation. Instagram has proven that potential with close to 150 million users. In technology, since most platforms are so scalable, those looking to acquire these technologies project 2, 3 and 5-years out in time to see where the product could be, and usually pay a multiple based on future potential, not actual results at the time. This bodes well for LiveDeal and its online and mobile deal engine, livedeal.com. LiveDeal seems to understand that the name of the game is potential and that building a technology's popularity by increasing its number of users could equate to more and more dollars in the company's future. With each major city that the company has added to its platform, there is the market to add thousands of new restaurants to create promotions and potentially millions of new consumers to view and use those real-time deals. Because LiveDeal's platform gives the restaurant owner all of the control, creates a direct relationship between merchant and consumer and eliminates the middleman by letting consumers pay for the promotions found on livedeal.com directly to the restaurant, the platform has to be taken seriously in the industry. Other online deal sites in the industry don't offer all of these advantages, so using a media campaign to drive more and more users to the company's platform should only serve to make this model the way merchants advertise promotions and consumers find their deals well into the future. www.stockwatch.com/News/Item.aspx?bid=U-z10073394-U%3aNVLX-20140320&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 25, 2014 8:47:44 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Apr 1, 2014 8:06:11 GMT -5
|
|
